PMS-METOCLOPRAMIDE HYDROCHLORIDE INJECTION SOLUTION

Ország: Kanada

Nyelv: angol

Forrás: Health Canada

Aktív összetevők:

METOCLOPRAMIDE HYDROCHLORIDE

Beszerezhető a:

PHARMASCIENCE INC

ATC-kód:

A03FA01

INN (nemzetközi neve):

METOCLOPRAMIDE

Adagolás:

5MG

Gyógyszerészeti forma:

SOLUTION

Összetétel:

METOCLOPRAMIDE HYDROCHLORIDE 5MG

Az alkalmazás módja:

INTRAMUSCULAR

db csomag:

15G/50G

Recept típusa:

Prescription

Terápiás terület:

PROKINETIC AGENTS

Termék összefoglaló:

Active ingredient group (AIG) number: 0109394003; AHFS:

Engedélyezési státusz:

APPROVED

Engedély dátuma:

2021-01-11

Termékjellemzők

_ _
_pms-METOCLOPRAMIDE Product Monograph Page 1 of 20_
PRODUCT MONOGRAPH
PR
PMS-METOCLOPRAMIDE TABLETS
Metoclopramide Tablets, USP
5 mg and 10 mg
PR
PMS-METOCLOPRAMIDE ORAL SOLUTION
Metoclopramide Oral Solution, USP
1 mg/mL
ANTIEMETIC
MODIFIER OF UPPER GASTROINTESTINAL TRACT MOTILITY
PHARMASCIENCE INC.
6111 Royalmount Ave., Suite 100
Montreal, Quebec
H4P 2T4
www.pharmascience.com
Date of Revision:
October 26, 2021
Submission Control No.: 256994
_ _
_pms-METOCLOPRAMIDE Product Monograph Page 2 of 20_
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
.........................................................3
SUMMARY PRODUCT INFORMATION
........................................................................3
INDICATIONS AND CLINICAL USE
..............................................................................3
CONTRAINDICATIONS
...................................................................................................4
WARNINGS AND PRECAUTIONS
..................................................................................4
ADVERSE REACTIONS
....................................................................................................6
DRUG INTERACTIONS
....................................................................................................7
DOSAGE AND ADMINISTRATION
................................................................................8
OVERDOSAGE
..................................................................................................................9
ACTION AND CLINICAL PHARMACOLOGY
..............................................................9
STORAGE AND STABILITY
..........................................................................................10
DOSAGE FORMS, COMPOSITION AND PACKAGING
.............................................10
PART II: SCIENTIFIC INFORMATION
...............................................................................11
PHARMACEUTICAL INFORMATION
......................................................................